From Constitutional Attack to Statutory Combat: The Next Wave of Medicare Drug-Price Litigation
By: Jimmie L. Bullock Background On May 18, 2026, the Supreme Court declined to review six pharmaceutical manufacturers’ challenges to the Medicare Drug Price Negotiation Program (MDPNP). For nearly three years, manufacturers had… Read more »